These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28562096)

  • 1. Emerging growth factor receptor antagonists for the treatment of advanced melanoma.
    Fenton SE; Sosman JA; Chandra S
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):165-174. PubMed ID: 28562096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of novel therapies for melanoma.
    Karimkhani C; Gonzalez R; Dellavalle RP
    Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
    McKibbin T
    Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging targeted therapies for melanoma.
    Johnson DB; Pollack MH; Sosman JA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis in malignant melanoma.
    Felcht M; Thomas M
    J Dtsch Dermatol Ges; 2015 Feb; 13(2):125-36. PubMed ID: 25631130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
    Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
    Yang GW; Jiang JS; Lu WQ
    Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
    Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
    Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel drugs in clinical development for hepatocellular carcinoma.
    Waidmann O; Trojan J
    Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma.
    Abe R; Fujita Y; Yamagishi S
    Mini Rev Med Chem; 2007 Jun; 7(6):649-61. PubMed ID: 17584162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.